Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology


Metformin: old dog, new tricks

ea0035s16.1 | Metformin: old dog, new tricks | ECE2014

Abstract unavailable....

ea0035s16.2 | Metformin: old dog, new tricks | ECE2014

Mechanisms of antitumoral activity of metformin in thyroid cancer

Derwahl Michael

The relative risk associated with diabetes and obesity is significantly higher for different carcinomas including thyroid cancer. There is some evidence that insulin resistance and as a consequence hyperinsulinemia rather than hyperglycemia are responsible for the higher prevalence of cancer in diabetic and obese patients. In the thyroid insulin/IGF-depending signalling is part of the mitogenic pathways that regulate benign and malignant growth. In diabetics with hyperinsuline...

ea0035s16.3 | Metformin: old dog, new tricks | ECE2014

Antitumoral effects of metformin on cancer stem cells: identification of novel molecular targets

Wurth Roberto , Gritti Marta , Angelini Marina , Barbieri Federica , Mazzanti Michele , Florio Tullio

Epidemiological and preclinical studies propose that metformin, a first-line drug for type- 2 diabetes, exerts direct antitumoral activity. Although several clinical trials are currently ongoing, the molecular mechanisms of this effect are unknown. The AMP-activated kinase-dependent pathway, and the down-stream effectors (e.g. mTOR) are considered the main effectors. Several studies reported the involvement of, in metformin metabolic activity. Nevertheless, contrasting evidenc...